Global Naloxone Market, by Strength (2.0 mg/0.1 ml and 4.0 mg/ml, 1 mg/ml, 0.4 mg/ml, and Others), by Route of Administration (Intranasal, Intramuscular/Subcutaneous, and Intravenous), by Distribution Channel (Hospitals, (Public Hospitals and Private Hospitals), Clinics (Including Addiction Clinics), Retail Pharmacies, Emergency Medical Services (EMS), Military Facilities, Miscellaneous Facilities, Online Pharmacies, and Others (long-term care facilities, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,118.3 Million in 2022, and is expected to exhibit a CAGR of 10.4% during the forecast period (2022-2030).
Market players are involved in product launches or approvals, which is expected to drive growth of the market over the forecast period. For instance, in March 2020, Dr. Reddy's Laboratories, an India-based multinational pharmaceutical company, launched Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) in the U.S. market. It is a single-dose prefilled syringe.
Market players are focused on adopting strategies such as agreements, acquisitions, etc., which is expected to boost growth of the global naloxone market over forecast period. For instance, in August 2019, Hikma Pharmaceuticals PLC signed an asset purchase agreement with Insys Therapeutics Inc., a U.S.-based pharmaceutical company to acquire a complementary manufacturing platform and two pipeline products. Under this agreement, Hikma agreed to acquire unit-dose nasal and sublingual spray manufacturing equipment, as well as two pipeline products, naloxone 505(b) (2) nasal spray and epinephrine 505(b) (2) nasal spray.
Global Naloxone Market - Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic has affected several markets across the globe. The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and impacting firms and markets financially.
The impact of COVID-19 on the global naloxone market was significant, owing to limiting the use of intranasal naloxone. For instance, according to review in Healio, 2021, there was a reduction of 26.32% in the number filled naloxone prescriptions in the U.S. in March 2020, which outpaced the 14.76% reduction in prescriptions filled for any medication and the 8.71% reduction in filled opioid prescriptions.
Browse 35 Market Data Tables and 36 Figures spread through 207 Pages and in-depth TOC on Global naloxone Market, by Strength (2.0 mg/0.1 ml and 4.0 mg/ml, 1 mg/ml, 0.4 mg/ml, and Others), by Route of Administration (Intranasal, Intramuscular/Subcutaneous, and Intravenous), by Distribution Channel (Hospitals, (Public Hospitals and Private Hospitals), Clinics (Including Addiction Clinics), Retail Pharmacies, Emergency Medical Services (EMS), Military Facilities, Miscellaneous Facilities, Online Pharmacies, and Others (long-term care facilities, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the global naloxone market, click the link below:
https://www.coherentmarketinsights.com/market-insight/naloxone-market-1804
Key Takeaways of the global naloxone market:
- Global naloxone market is expected to exhibit a CAGR of 10.6% over the forecast period (2022-2030). North America is expected to account for major market share over the forecast period (2022-2030), owing to increasing initiatives by various health agencies to prevent deaths due to drug. For instance, in October 2021, the Centers for Disease Control and Prevention, the national public health agency of the U.S., launched four complementary education campaigns in the U.S. for young adults with age 18-34 years. This campaign provides information regarding the prevalence of fentanyl, the consequences and risks of mixing drugs, and the life-saving ability of naloxone.
- Some of the major players operating in the global naloxone market include Viatris Inc., Opiant Pharmaceuticals, Akorn Operating Company LLC, Pfizer, Inc., Novartis AG, Indivior Plc., Emergent BioSolutions Inc., Amphastar Pharmaceuticals, Inc., Kern Pharma, S.L., Hikma Pharmaceuticals PLC, Mundipharma International Limited, and Kaleo, Inc.
